Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Primary Purpose
Central Serous Chorioretinopathy
Status
Unknown status
Phase
Phase 2
Locations
Mexico
Study Type
Interventional
Intervention
Intravitreal injection of Bevacizumab
Sponsored by
About this trial
This is an interventional treatment trial for Central Serous Chorioretinopathy
Eligibility Criteria
Inclusion Criteria
- Any visual acuity.
- Central serous chorioretinopathy
Sites / Locations
- Asociacion para Evitar la Ceguera en MexicoRecruiting
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00418431
First Posted
January 3, 2007
Last Updated
January 3, 2007
Sponsor
Asociación para Evitar la Ceguera en México
1. Study Identification
Unique Protocol Identification Number
NCT00418431
Brief Title
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
Study Type
Interventional
2. Study Status
Record Verification Date
June 2006
Overall Recruitment Status
Unknown status
Study Start Date
April 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2006 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Asociación para Evitar la Ceguera en México
4. Oversight
5. Study Description
Brief Summary
Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment.
The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Central Serous Chorioretinopathy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Intravitreal injection of Bevacizumab
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
50 Years
Eligibility Criteria
Inclusion Criteria
Any visual acuity.
Central serous chorioretinopathy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mitzy E Torres Soriano, MD
Phone
525510841400
Ext
1172
Email
retinamex@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Hugo Quiroz-Mercado, MD
Phone
525510841400
Ext
1171
Email
hugoquiroz@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mitzy E Torres Soriano, MD
Organizational Affiliation
Asociación para Evitar la Ceguera en México
Official's Role
Principal Investigator
Facility Information:
Facility Name
Asociacion para Evitar la Ceguera en Mexico
City
Mexico DF
State/Province
DF
ZIP/Postal Code
04030
Country
Mexico
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mitzy E Torres Soriano, MD
Phone
5255510841400
Ext
1171
Email
mitzytorres@yahoo.com
First Name & Middle Initial & Last Name & Degree
Maura Abraham, MD
First Name & Middle Initial & Last Name & Degree
Orlando Ustariz, MD
First Name & Middle Initial & Last Name & Degree
Gerardo Garcia Aguirre
First Name & Middle Initial & Last Name & Degree
Veronica Kon-Jara, MD
First Name & Middle Initial & Last Name & Degree
Hugo Quiroz-Mercado, MD
First Name & Middle Initial & Last Name & Degree
Jose L Guerrero, MD
12. IPD Sharing Statement
Learn more about this trial
Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy
We'll reach out to this number within 24 hrs